Statin Toxicity From Macrolide Antibiotic Coprescription

@article{Patel2013StatinTF,
  title={Statin Toxicity From Macrolide Antibiotic Coprescription},
  author={A. Patel and S. Shariff and D. Bailey and D. Juurlink and Sonja Gandhi and M. Mamdani and T. Gomes and J. Fleet and Y. J. Hwang and A. Garg},
  journal={Annals of Internal Medicine},
  year={2013},
  volume={158},
  pages={869 - 876}
}
BACKGROUND Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4. OBJECTIVE To measure the frequency of statin toxicity after coprescription of a statin with clarithromycin or erythromycin. DESIGN Population-based cohort study. SETTING Ontario, Canada, from 2003 to 2010. PATIENTS Continuous statin users older than 65 years who were prescribed… Expand
65 Citations
Outcomes Following Macrolide Use in Kidney Transplant Recipients
  • 4
Co-Medication of Statins with Contraindicated Drugs
  • 7
  • PDF
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers
  • 29
  • Highly Influenced
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors
  • 41
Statin–macrolide interaction risk: a population-based study throughout a general practice database
  • 34
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
  • 824
  • PDF
Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations
  • 100
Steady‐State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid‐Lowering Agent Rosuvastatin
  • 31
...
1
2
3
4
5
...